TPST: Huge Potential to Go Up!
$Tempest Therapeutics Inc.(TPST)$
Shorts trying to take a scenario they have never seen before and apply useless data that isn’t relevant to what this stock is really worth..
The price can tell you anything they want as long as they make money on the short side..This stock is moving up!
This stock is a unicorn!
100 million market cap. The cost of the Roche treatment (used together with TPST-1120) alone costs $322k a year.
There are 800k people diagnosed with liver cancer every year, 700k die from it annually.
But TPST made a huge progress here!
From the Ppt & confirmed call, the confirmed objective response rate (cORR or confirmed ORR) was 30% for the TPST-1120 triplet arm (ie versus 13.3% for the atezolizumab + bevacizumab control arm)....!
40% of the patients in the TPST-1120 arm were on treatment (16/40) compared to 16.7% in the atezolizumab + bevacizumab control arm (5/30).
TPST-1120 also remains surprisingly well tolerated, with safety data comparable between the two arms.
Wait until the greed kicks in 😉 a 200% increase in pancreatic cancer survival is worth billions alone.
With positive data about to be released this run will be unstoppable!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
